The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …
Endometriosis is a chronic inflammatory condition characterized by the presence of endometrial-like tissue outside the uterine cavity. Despite significant advances in understanding its pathophysiology, the clinical management of endometriosis remains …
Endometriosis is a chronic, estrogen-dependent inflammatory disorder characterized by the ectopic implantation and persistence of endometrial-like tissue outside the uterine cavity. Despite its high prevalence and significant impact on quality …
Pain is influenced by a complex interplay of biological, psychological, and social factors. Sex has emerged as a key determinant of vulnerability to chronic pain and a major risk factor …
Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10-15% of women of reproductive age globally and is characterized …
Surgery is chosen over pharmacological treatment, probably due to the limitations of medical therapy, pregnancy, the preferences of patients and physicians, and the psychological perception of a more definitive symptom …
Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …
Virtual reality (VR) based technology may offer new avenues in the management of chronic endometriosis-related pain. Our prospective, 14-week, open, three-phase, cross-over pilot study investigated whether the use of VR …
Endometriosis affects 10-15% of people assigned female at birth and can cause chronic pelvic pain and impair many domains of quality of life, such as fertility, mood and bladder, bowel …